Treatment toxicity and efficacy in 177 patients with lymphoma who had an HIV score of 1, according to HAART era
Patients with HIV score of 1 . | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| . | CHOP . | Ld-CHOP . | CHOP . | Ld-CHOP . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 11 (22) | 6 (14) | 12 (27) | 5 (13) | ||
| Leukocytes | 25 (49) | 13 (30) | 24 (54)* | 12 (32)* | ||
| Infection | 6 (12) | 5 (11) | 9 (20) | 6 (16) | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 27 (53)* | 14 (32)* | 20 (45) | 12 (32) | ||
| 3-y OS, % (95% Cl) | 19 (8, 31) | 16 (5, 28) | 38 (23, 53) | 30 (16, 46) | ||
| 3-y EFS, % (95% Cl) | 17 (5, 19) | 17 (6, 28) | 36 (21, 59) | 28 (14, 43) | ||
| 3-y DFS, % (95% Cl) | 23 (7, 39) | 23 (1, 45) | 69 (47, 92) | 50 (19, 81) | ||
Patients with HIV score of 1 . | Before HAART . | . | After HAART . | . | ||
|---|---|---|---|---|---|---|
| . | CHOP . | Ld-CHOP . | CHOP . | Ld-CHOP . | ||
| Toxicity grade 3-4, no. (%) | ||||||
| Platelets | 11 (22) | 6 (14) | 12 (27) | 5 (13) | ||
| Leukocytes | 25 (49) | 13 (30) | 24 (54)* | 12 (32)* | ||
| Infection | 6 (12) | 5 (11) | 9 (20) | 6 (16) | ||
| Response to chemotherapy | ||||||
| CR/Cru, no. (%) | 27 (53)* | 14 (32)* | 20 (45) | 12 (32) | ||
| 3-y OS, % (95% Cl) | 19 (8, 31) | 16 (5, 28) | 38 (23, 53) | 30 (16, 46) | ||
| 3-y EFS, % (95% Cl) | 17 (5, 19) | 17 (6, 28) | 36 (21, 59) | 28 (14, 43) | ||
| 3-y DFS, % (95% Cl) | 23 (7, 39) | 23 (1, 45) | 69 (47, 92) | 50 (19, 81) | ||
For pre-HAART patients on CHOP, n = 51; on Ld-CHOP, n = 44. For post-HAART patients on CHOP, n = 44; on Ld-CHOP, n = 38.
Comparison between treatment arms within the HAART era: P ≤ .05.